A comparison of nontraditional atherogenic markers with pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

被引：0
|
作者：
Law, R
Khan, M
Perez, A
Jacober, S
Goldberg, R
Kendall, D
Deeg, M
Tan, M
Demissie, S
机构：
[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[2] Univ Miami, Sch Med, Div Endocrinol Diabet & Metab, Coral Gables, FL 33124 USA
[3] Pk Nicollet Inst, Int Diabet Ctr, Minneapolis, MN USA
[4] Indiana Univ, Sch Med, Dept Vet Affairs, Indianapolis, IN 46204 USA
来源：
DIABETOLOGIA | 2005年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
788
引用
收藏
页码：A286 / A286
页数：1
相关论文
共 50 条
  • [1] Comparison of pioglitazone (PIO) and rosiglitazone (ROSI) on atherogenic index of plasma (AIP) in patients with type 2 diabetes and dyslipidemia
    Tan, MH
    Deeg, MA
    Goldberg, RB
    Buse, JB
    Kendall, DM
    Zagar, AJ
    Khan, MA
    Perez, AT
    Jacober, SJ
    [J]. DIABETES, 2005, 54 : A1 - A1
  • [2] A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
    Goldberg, RB
    Kendall, DM
    Deeg, MA
    Buse, JB
    Zagar, AJ
    Pinaire, JA
    Tan, MH
    Khan, MA
    Perez, AT
    Jacober, SJ
    [J]. CIRCULATION, 2005, 111 (13) : 1727 - 1728
  • [3] A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
    Goldberg, RB
    Kendall, DM
    Deeg, MA
    Buse, JB
    Zagar, AJ
    Pinaire, JA
    Tan, MH
    Khan, MA
    Perez, AT
    Jacober, SJ
    [J]. DIABETES CARE, 2005, 28 (07) : 1547 - 1554
  • [4] A comparison of effects of pioglitazone and rosiglitazone on serum lipoproteins and their subfractions in patients with type 2 diabetes and dyslipidemia
    Tan, MH
    Kendall, DM
    Deeg, MA
    Buse, JB
    Goldberg, R
    Zagar, AJ
    Khan, MA
    Perez, AT
    Jacober, SJ
    [J]. DIABETOLOGIA, 2005, 48 : A393 - A394
  • [5] The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus
    Rosenblatt, S
    Miskin, B
    Glazer, NB
    Prince, MJ
    Robertson, KE
    [J]. CORONARY ARTERY DISEASE, 2001, 12 (05) : 413 - 423
  • [6] A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia - Response to Bell and Brunzell
    Goldberg, RB
    Kendall, DM
    Deeg, MA
    Buse, JB
    Zagar, AJ
    Pinaire, JA
    Tan, MH
    Khan, MA
    Perez, AT
    Jacober, SJ
    [J]. DIABETES CARE, 2005, 28 (12) : 2985 - 2986
  • [7] A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia - Response to Goldberg et al.
    Brunzell, JD
    [J]. DIABETES CARE, 2005, 28 (12) : 2984 - 2985
  • [8] Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US
    Tunis, Sandra L.
    Minshall, Michael E.
    Charles, Meaghan St.
    Pandya, Bhavik J.
    Baran, Robert W.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (11) : 3085 - 3096
  • [9] The comparative effects of pioglitazone and rosiglitazone on lipoprotein sub-fractions in patients with type 2 diabetes and dyslipidemia
    Deeg, MA
    Goldberg, RB
    Buse, JB
    Kendall, DM
    Zagar, AJ
    Pinaire, JA
    Tan, MH
    Khan, MA
    Perez, AT
    Jacober, SJ
    [J]. DIABETES, 2005, 54 : A234 - A235
  • [10] Rosiglitazone or pioglitazone in type 2 diabetes?
    de Vries, Corinne S.
    Russell-Jones, David L.
    [J]. BRITISH MEDICAL JOURNAL, 2009, 339
12345